Advertisement
Screener

ELI LILLY AND COMPANY (LLY) Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation (Deprecated 2012-01-31)

2.8 / 5 stars · 68/120 Roast Me

ELI LILLY AND COMPANY Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation (Deprecated 2012-01-31)

ELI LILLY AND COMPANY (LLY) reported Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation (Deprecated 2012-01-31) of $187.10 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-24.

Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Roll Forwards

us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation · last filed 2012-02-24

  • ELI LILLY AND COMPANY defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation (deprecated 2012-01-31) for fiscal 2011 was $187.10M, a 14.02% increase from fiscal 2010.
  • ELI LILLY AND COMPANY defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation (deprecated 2012-01-31) for fiscal 2010 was $164.10M.
Period endDefined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation (Deprecated 2012-01-31) 12 month
2011-12-31$187.10M
10-K · filed 2012-02-24
2010-12-31$164.10M
10-K · filed 2011-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
Akari Therapeutics Plc (AKTX)$1,527.991B-47,921.42
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
AbbVie Inc. (ABBV)United States$468.180B70.37
Merck & Co., Inc. (MRK)United States$365.215B99.96
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94